Value of Genetic Testing for Lipoprotein(a) Variants.

Abstract readEditorialComment

In one paragraph

Article in Circulation. Genomic and precision medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification.Frontiers in cardiovascular medicine · 2026
Review
Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review.American heart journal plus : cardiology research and practice · 2025
Review
Striving Towards Equity in Cardiovascular Genomics Research.Current atherosclerosis reports · 2025
Review
Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.European journal of preventive cardiology · 2025
Article
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk.Current vascular pharmacology · 2024
Review
Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood.Circulation · 2023
Article

4 · The record

Corrections and comments

Comment on
Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.2022

5 · Who and what money

Authors and funding

2 authors.

Anne LangstedDepartment of Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark. Department of Clinical Medicine Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.ORCID 0000-0002-0201-7223

Børge G NordestgaardDepartment of Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark. Department of Clinical Medicine Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.ORCID 0000-0002-1954-7220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hyperlipoproteinemia Type IILipoprotein(a)Genetic TestingHumansLipoprotein(a)cardiovascular risk factorsEditorialsgenetic testinghypercholesterolemia, familialscreening

Identifiers

PMID35311528

DOI10.1161/CIRCGEN.122.003737

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.